Literature DB >> 22698692

Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription.

B Reed1, N Fang, B Mayer-Blackwell, S Chen, V Yuferov, Y Zhou, M J Kreek.   

Abstract

Antagonism of the kappa opioid receptor (KOR) has been reported to have anti-depressant-like properties. The dynorphin/KOR system is a crucial neurochemical substrate underlying the pathologies of addictive diseases, affective disorders and other disease states. However, the molecular underpinnings and neuroanatomical localization of the dysregulation of this system have not yet been fully elucidated. Utilizing the Porsolt Forced Swim Test (FST), an acute stressor commonly used as in rodent models measuring antidepressant efficacy, male Sprague-Dawley rats were subject to forced swimming for 15 min, treated 1h with vehicle or norbinaltorphimine (nor-BNI) (5 or 10mg/kg), and then 1 day later subject to FST for 5 min. In accordance with previous findings, nor-BNI dose dependently increased climbing time and reduced immobility. In comparison to control animals not exposed to FST, we observed a significant elevation in prodynorphin (pDyn) mRNA levels following FST using real-time optical polymerase chain reaction (PCR) in the caudate putamen but not in the nucleus accumbens, hypothalamus, amygdala, frontal cortex, or hippocampus. nor-BNI treatment did not affect pDyn mRNA levels in comparison to animals that received vehicle. The corresponding brain regions from the opposite hemisphere were analyzed for underlying chromatin modifications of the prodynorphin gene promoter region using chromatin immunoprecipitation with antibodies against specifically methylated histones H3K27Me2, H3K27Me3, H3K4Me2, and H3K4Me3, as well as CREB-1 and MeCP2. Significant alterations in proteins bound to DNA in the Cre-3, Cre-4, and Sp1 regions of the prodynorphin promoter were found in the caudate putamen of the FST saline-treated animals compared to control animals, with no changes observed in the hippocampus. Epigenetic changes resulting in elevated dynorphin levels specifically in the caudate putamen may in part underlie the enduring effects of stress.
Copyright © 2012 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698692      PMCID: PMC3412925          DOI: 10.1016/j.neuroscience.2012.06.006

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  46 in total

Review 1.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

Review 2.  A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder.

Authors:  Andrew A Nierenberg; Michael J Ostacher; Jeffrey C Huffman; Rebecca M Ametrano; Maurizio Fava; Roy H Perlis
Journal:  J Occup Environ Med       Date:  2008-04       Impact factor: 2.162

3.  Relative expression of mRNA for the somatostatin receptors in the caudate putamen of C57BL/6J and 129P3/J mice: strain and heroin effects.

Authors:  Stefan D Schlussman; Jared Cassin; Orna Levran; Yong Zhang; Ann Ho; Mary Jeanne Kreek
Journal:  Brain Res       Date:  2010-05-15       Impact factor: 3.252

4.  Regulation of hippocampal H3 histone methylation by acute and chronic stress.

Authors:  Richard G Hunter; Katharine J McCarthy; Thomas A Milne; Donald W Pfaff; Bruce S McEwen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

Review 5.  Molecular and genetic substrates linking stress and addiction.

Authors:  Lisa A Briand; Julie A Blendy
Journal:  Brain Res       Date:  2009-11-10       Impact factor: 3.252

6.  Essential role of the histone methyltransferase G9a in cocaine-induced plasticity.

Authors:  Ian Maze; Herbert E Covington; David M Dietz; Quincey LaPlant; William Renthal; Scott J Russo; Max Mechanic; Ezekiell Mouzon; Rachael L Neve; Stephen J Haggarty; Yanhua Ren; Srihari C Sampath; Yasmin L Hurd; Paul Greengard; Alexander Tarakhovsky; Anne Schaefer; Eric J Nestler
Journal:  Science       Date:  2010-01-08       Impact factor: 47.728

7.  Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.

Authors:  Gregory V Carr; Debra A Bangasser; Thelma Bethea; Matthew Young; Rita J Valentino; Irwin Lucki
Journal:  Neuropsychopharmacology       Date:  2009-11-18       Impact factor: 7.853

8.  Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models.

Authors:  Matthew B Wilkinson; Guanghua Xiao; Arvind Kumar; Quincey LaPlant; William Renthal; Devanjan Sikder; Thomas J Kodadek; Eric J Nestler
Journal:  J Neurosci       Date:  2009-06-17       Impact factor: 6.167

9.  Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue.

Authors:  Elena H Chartoff; Maria Papadopoulou; Matt L MacDonald; Aram Parsegian; David Potter; Christine Konradi; William A Carlezon
Journal:  Mol Pharmacol       Date:  2008-12-23       Impact factor: 4.436

10.  The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system.

Authors:  Benjamin B Land; Michael R Bruchas; Julia C Lemos; Mei Xu; Erica J Melief; Charles Chavkin
Journal:  J Neurosci       Date:  2008-01-09       Impact factor: 6.167

View more
  12 in total

1.  Impact of Pharmacological Manipulation of the κ-Opioid Receptor System on Self-grooming and Anhedonic-like Behaviors in Male Mice.

Authors:  Eduardo R Butelman; Bryan D McElroy; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2019-04-11       Impact factor: 4.030

2.  Can a rapid measure of self-exposure to drugs of abuse provide dimensional information on depression comorbidity?

Authors:  Eduardo Roque Butelman; Silvia Bacciardi; Angelo Giovanni Icro Maremmani; Maya Darst-Campbell; Joel Correa da Rosa; Mary Jeanne Kreek
Journal:  Am J Addict       Date:  2017-06-27

3.  "Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats".

Authors:  Marta Valenza; Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2017-05-27       Impact factor: 4.530

4.  Dynorphin/Kappa Opioid Receptor Activity Within the Extended Amygdala Contributes to Stress-Enhanced Alcohol Drinking in Mice.

Authors:  Harold L Haun; Christina L Lebonville; Matthew G Solomon; William C Griffin; Marcelo F Lopez; Howard C Becker
Journal:  Biol Psychiatry       Date:  2022-01-10       Impact factor: 12.810

Review 5.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 6.  Medications for substance use disorders (SUD): emerging approaches.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Expert Opin Emerg Drugs       Date:  2017-10-30       Impact factor: 4.191

7.  Effects of Kappa opioid receptor blockade by LY2444296 HCl, a selective short-acting antagonist, during chronic extended access cocaine self-administration and re-exposure in rat.

Authors:  Marta Valenza; Kyle A Windisch; Eduardo R Butelman; Brian Reed; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2020-01-08       Impact factor: 4.530

8.  Exposure to Prenatal Stress Is Associated With an Excitatory/Inhibitory Imbalance in Rat Prefrontal Cortex and Amygdala and an Increased Risk for Emotional Dysregulation.

Authors:  Francesca Marchisella; Kerstin Camile Creutzberg; Veronica Begni; Alice Sanson; Luis Eduardo Wearick-Silva; Saulo Gantes Tractenberg; Rodrigo Orso; Érika Kestering-Ferreira; Rodrigo Grassi-Oliveira; Marco Andrea Riva
Journal:  Front Cell Dev Biol       Date:  2021-06-01

Review 9.  Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Front Pharmacol       Date:  2015-09-08       Impact factor: 5.810

10.  Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.

Authors:  Brian Reed; Eduardo R Butelman; Rebecca S Fry; Rachel Kimani; Mary Jeanne Kreek
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.